Psilocybin is a classic serotonergic psychedelic and oral serotonin 2a/sigma 1 receptor-active compound that has been studied as a rapid-acting antidepressant and as a candidate for restoring mitochondrial integrity. In iPSC-derived neurons, it showed time-dependent transcriptomic effects, and its overall gene expression responses were highly correlated with other agents at matched timepoints, supporting a shared rapid-acting antidepressant signature. Clinically, it has been administered at a 25 mg oral dose in psilocybin-assisted psychotherapy and was associated with reduced anhedonia scores in treatment-resistant depression. Preclinical work also examined its behavioral effects in mice under an acute fluoxetine paradigm, where fluoxetine attenuated psilocybin efficacy. Overall, the literature links psilocybin to treatment resistant depression, anhedonia, and mechanistic hypotheses involving 5-HT2A and sigma-1 receptor signaling.
Neuropsychiatry / Depression
- Psilocybin was investigated as a rapid-acting antidepressant in neurons derived from individuals with treatment resistant depression; its transcriptomic effects were time-dependent in iPSC-derived neurons. (PMID:41743330)
- The study reported that overall gene expression responses were highly correlated among agents at matched timepoints, indicating a shared response pattern across rapid-acting antidepressant candidates. (PMID:41743330)
- Oral psilocybin was administered at a 25 mg dose in psilocybin-assisted psychotherapy and was associated with reduced anhedonia scores. (PMID:41690631)
- In the acute fluoxetine paradigm, fluoxetine attenuated psilocybin efficacy in mice, highlighting a potential drug–drug interaction relevant to clinical trial design. (PMID:41852641)
Mechanism / Neurobiology
- Psilocybin was discussed as a classic hallucinogen that may restore mitochondrial integrity by activating serotonin 2a receptors. (PMID:41707907)
- The same work also implicated sigma 1 receptor activation in the proposed mitochondrial mechanism. (PMID:41707907)
- These mechanistic hypotheses connect psilocybin to mitochondria-associated membranes and broader neurobiological effects relevant to neurodegenerative and psychiatric disease contexts. (PMID:41707907)